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The pleomorphic adenoma is a benign epithelial tumor originating from the major and 
minor salivary glands. It is the most common type of sa livary gland tumor, accounting for 
almost half of all neoplasms in these organs. Cytogenetically, pleomorphic adenomas are 
characterized by recurrent rearrangments involving the chromosome regions 3p21, 8ql2 and 
12ql3-15. The most frequent abnormality is a reciprocal t(3;8)(p21;ql2) translocation, or 
variants thereof in which the 8q segment is translocated to a variety of chromosome 
regions. The purpose of the present series of investigations was to identify the genes 
involved in the t(3;8)(p21;ql2) using a positional cloning approach. 
Y AC clones corresponding to known genetic markers flanking band 8ql2 were used to 
initiate a walk towards the 8ql2 breakpoints. This resulted in the establishment of two 
non-overlapping YAC contigs covering approximately 75% of b and 8ql2. The centromeric 
contig covers approximately 2 Mb of genomic DNA and consists of 34 overlapping YAC 
clones containing at least seven putative CpG islands, and three ESTs. The telomeric contig 
consists of 23 YACs and covers about 5 Mb of g enomic DNA. FISH mapping of YACs and 
cosmids from these contigs revealed that the majority of b reakpoints clustered within a 300 
kb subregion in the centromeric contig. Subsequent studies of new STSs and ESTs from this 
region led to the discovery of the PLAG1 gene, a novel, developmentally regulated gene 
coding for a zinc finger protein. 
The gene, which consists of 5 exons of w hich the first three are non-coding, spans about 
35 kb, with a large intron (approximately 25 kb) between exon 1 and exon 2. The deduced 
amino acid sequence of the PLAG1 protein reveals seven canonical C2H2 zinc finger domains 
in the N-terminal region and a serine-rich C-terminus. There are two potential nuclear 
localization signals in the N-terminal region. 5' RACE analysis of tumors with t(3;8) 
enabled us to identify CTNNB1 as the chromosome 3 gene fused to PLAG1. CTNNB1 codes 
for ß-catenin, a protein interface functioning in the WG/WNT signalling pathway and in 
the specification of ce ll fate during embryogenesis. 
The t(3;8) results in promoter swapping between PLAG1 and CTNNB1. Fusions 
invariably occur in the 5' non-coding regions of both genes, exchanging regulatory control 
elements while preserving the coding sequences. Due to the t(3;8) PLAG1 is activated 
whereas the expression of CTNNB1 is reduced. Activation of PLAG1 was also observed in 
an adenoma with a t(8;15)(ql2;ql4) translocation, demonstrating that PLAG1 activation is 
not restricted to tumors with t(3;8). To our knowledge this is the first example of p romoter 
swapping in solid tumors. 
The identification and cloning of a novel "benign oncogene" activated by chromosome 
translocation in pleomorphic adenomas constitute an important step towards an increased 
understanding of the molecular pathogenesis of benign neoplastic growth. The results 
potentially allow for the design of novel diagnostic tools and targeted therapy of 
pleomorphic adenomas. 
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CANCER GENETICS 
Introduction 
Cancer is nowadays recognized as being a genetic disease. At the 
beginning of this century, Boveri wrote Another possibility [to explain 
cancer] is the presence of definite chromosomes which inhibit division .... 
Cells of tumors with unlimited growth would arise if those "inhibiting 
chromosomes" were eliminated and [since] each kind of chromosome is 
represented twice in the normal cell, the depression of only one of these two 
might pass unnoticed (Boveri, 1914; translation published in 1929) Today 
it is well established that tumors are caused by mutations and 
rearrangements of specific classes of genes within the chromosomes 
(Bishop, 1987; Weinberg 1989a, b). Three classes of tumor-associated genes 
have been identified in particlar, namely oncogenes, tumor suppressor 
genes, and DNA repair genes (Bishop, 1991; Fishel and Kolodner, 1995). It is 
well established that the cells in a tumor descend from a common ancestral 
cell which at one point, usually decades before a tumor becomes palpable, 
acquired a mutation that initiated a program of inappropriate growth 
control. The progression of such a cell into a cancer cell comes about 
through the accumulation of a number of additional mutations. The initial 
mutation can either occur in a somatic cell, which may subsequently lead to 
a spontaneously induced tumor, or it can occur in a germ line cell, which 
results in an inherited predisposition to tumor development. Many solid 
tumors occur in both sporadic and hereditary forms, although the latter are, 
as a rule, much less common. 
The number of genetic events required for the conversion of a normal 
cell into a tumor cell is likely to vary for different cell types. In colorectal 
tumorigenesis for example, at least five to six events have been identified 
(Fig. 1) (Vogelstein and Kinzler, 1993), whereas in certain pediatric tumors, 
such as retinoblastoma and Wilms' tumor, only two mutations seem to be 
required (Knudson, 1985, 1987). The fact that most cancers occur in the fifth 
to seventh decades of life is a reflection of t he time it takes for an individual 
to accumulate enough mutations to cause malignancy. Although there 
seems to be some variability in the order of the mutations, there is also a 
definite preference, e.g. certain mutations are required for the initiation of 
tumorigenesis in certain cell types (Vogelstein and Kinzler, 1993). 
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Fig. 1. Proposed model for the development of colorectal carcinoma (from Vogelstein and 
Kinzler, 1993). 
The cell cycle 
All living organisms are dependent on the ability of cells to produce 
daughter cells. In the development of a zygote into an adult organism, the 
cell divisions in the different tissues and organs are strictly regulated so that 
cells only reproduce when instructed to do so by other cells in their vicinity. 
In cancer cells this carefully controlled program is violated, cancer cells no 
longer respond to the usual proliferation controls and instead they follow 
their own internal reproduction program. The cell cycle machinery, which 
seems to be very similar in most eukaryotic organisms, was first studied in 
detail in yeast cells. The cell cycle is subdivided into four stages: Gl, S, G2 
and M (Fig. 2). Most differentiated, adult cells are in the Gi-phase (gap 1). In 
the absence of stimulatory signals the cell will arrest early in Gl in a phase 
called Go- During Gl the cell checks the integrity of the DNA, synthesizes 
and accumulates the material necessary for cell division, and prepares for 
DNA-synthesis. When stimulated by mitogens, and under the right 
conditions, the cell will pass through the restriction point, START, or "point 
of no return" and proceed to the S-phase (for synthesis) where the 
chromosomal DNA is replicated. The cell thereafter enters a second, shorter 
gap phase (G2) after which it moves on to mitosis (M). During the M-phase 
the cell devide into two identical daughter cells containing a complete set of 
the genetic material (Watson et al, 1992; MacLachlan et al, 1995). 
Cell cycle control 
The regulation of the mammalian cell cycle is very complex (Fig. 2). At 
first, one molecule, cdc2, was thought to be the only key player. Today, seven 
related so-called cyclin-dependent-kinases (CDKs) are known to play a 
central role in regulating the entrance into the various stages of the cell 
cycle. The CDKs are activated by larger proteins, termed cyclins. CDKs must 
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also be activated by phosphorylation of a conserved threonine. Recent 
studies have shown that CDKs are also regulated by small proteins acting as 
cyclin-dependent-kinase inhibitors. In, for example, Gl the D-type cyclins 
bind to CDK4 and CDK6 and thereby induce a new cell cycle. The resulting 
complex acts on the growth-inhibitory molecule pRB. When pRB is 
phosphorylated by the complex it cannot bind and inactivate the 
transcription factor E2F, a factor necessary for progression into the S-phase. 
This action thus releases the braking effect of pRB and enables the cell to 
progress to the next phase. As shown in Fig. 2 the expression of cyclin D is 
followed by the induction of the E-, A-, and B-type cyclins. Abnormal 
expression of the various proteins involved in the cell cycle machinery is 
often seen in human cancer (MacLachlan et al., 1995). 
Fig. 2. Schematic view of the mammalian cell cycle (modified after MacLachan et al., 1995). 
Oncogenes 
Oncogenes are normal cellular genes (also called proto-oncogenes) which 
are highly conserved through evolution. The human genome contains 
about 100 known proto-oncogenes that may be converted into oncogenes by 
specific genetic alterations. Oncogenes are very heterogeneous with regard to 
their functions. Their protein products may act at different levels in the 
cellular machinery. They are key factors in signal transduction pathways, 
starting with growth factors and their receptors via complex systems of 
cytoplasmic transducers to transcription factors in the nucleus (Weinberg, 
1 cdk2 
B1+A 
START 
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1991; Morris, 1992a, b; Sleeman, 1992; Levine and Broach, 1995). These very 
complex cellular systems are strictly regulated, and it is the abnormal 
expression or the expression of altered protein products of genes within 
these systems that conduce to neoplasia (Bishop, 1991). Proto-oncogenes can 
be activated by several different mechanisms, including point mutations, 
gene truncation, gene amplification, and gross chromosomal 
rearrangements such as translocations, insertions, and inversions. Activated 
oncogenes may thus encode normal gene products, mutated gene products 
as well as novel fusion proteins. An oncogene can be activated by more than 
one mechanism. The MYC gene, for example, is amplified in certain tumors 
and activated by chromosomal translocations in others. MYC may also act as 
a retroviral oncogene (Heim and Mitelman, 1995; Cooper, 1990). On the basis 
of s equence and functional similarities, oncogenes can be grouped into gene 
families. They can also be grouped into classes depending on the site of 
action of their protein products(Weinberg, 1989a; Cooper, 1990). 
The first oncogene was discovered in 1976 when Bishop, Varmus and co­
workers found that the transforming gene of Rous sarcoma virus, a 
retrovirus that causes cancer in chicken, wa s a cellular gene named SRC 
(Stehlin et al, 1976). Since then more than 20 retroviral oncogenes have 
been identified, including MYC,ERBB,MOS and ABL. They are all 
integrated into the genome of acutely transforming viruses, and are 
expressed as independent translation products or as fusion proteins 
containing viral sequences (Cooper, 1990). These viruses are capable of 
inducing tumors in animals with short latency periods and to efficiently 
transform cells in vitro. The discovery of these genes provides important 
evidence that cancer is a genetic disease caused by specific genes. 
Growth factors.  Th e first known physiological function of an oncogene 
product was described for the SIS gene. SIS was shown to be homologous to 
the platelet-derived growth factor (PDGF) B-chain (Doolittle et al., 1983; 
Waterfield et al., 1983). The biologically active PDGF molecule is a dimer of 
A- and/or B-chains. The A- and B-chains are encoded by different genes 
located on different chromosomes (PDGFA maps to 7p22 and PDGFB to 
22ql3; Stenman et al; 1992a; Swan et al,1982). Only cells expressing a PDGF 
receptor on its surface, such as fibroblasts and smooth muscle cells, are 
susceptible to transformation by SIS (Cooper, 1990). Other known examples 
of oncogenes encoding growth factors are INT2,HST and FGF5, which are 
all members of the fibroblast growth factor family (Nguyen et al, 1988; 
Maries et al, 1989), as well as the epidermal growth factor (EGF) and the 
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related transforming growth factor-a ('TGF-a) (Derynck, 1988; Di Marco et  a l . ,  
1989). 
Growth facto r  receptors .  There are a number of growth factor receptors 
with protein-tyrosine kinase activity that can act as oncogenes. Binding of a 
ligand to such a receptor stimulates the tyrosine kinase activity. Mutations 
in these genes can result in constitutive activation of the receptor tyrosine 
kinases .  Examples  of  such genes are  ERBB,  FMS,  ERBB2,  TRK,  RET,  MET,  
and KIT. The ERBB gene, which codes for the epidermal growth factor 
receptor (EGFR), is activated by a deletion of the ligand-binding domain of 
the receptor (Wells and Bishop, 1988). The EGFR gene is often amplified in, 
f o r  e x a m p l e ,  m a l i g n a n t  g l i o m a s  ( C o l l i n s ,  1 9 9 5 ) .  S i m i l a r l y ,  t h e  F M S  
oncogene, which is homologous to the macrophage colony-stimulating 
factor (CSF-1) r eceptor (Sherr et al, 1985), is activated by a point mutation in 
the extracellular domain of the receptor. A third example of an oncogene 
coding for  a  growth factor  receptor  is  ERBB2 (a lso referred to  as  HER2/NEU).  
ERBB2 is  a  member of  the ERBB-l ike gene family but  is  dis t inct  f rom ERBB.  
ERBB2 is often amplified and/or overexpressed in breast and ovarian cancer 
(Slamon et al., 1989) as well as in malignant salivary gland tumors 
(Stenman et al., 1991b). 
Cytoplasmic  oncoprote ins .  Oncogenes acting in the cytoplasm are often 
protein-tyrosine kinases that function as signal transducers and transmittors 
activating protein cascades. The SRC oncogene is the protype of this group. 
The members of the SRC subfamily - SRC, YES, FGR, LCK, FYN, LYN and 
HCK - are all associated with the plasma membrane and are activated by 
phosphorylation at important tyrosine residues. They also contain amino-
terminal regulatory domains designated SH-2 and SH-3. These domains are 
also conserved in the ABL oncogene product, while only the SH-3 domain 
is conserved in the FES oncogene product (Cooper, 1990). Other kinases, 
such as MOS and RAF, are soluble cytoplasmic proteins with 
serine/threonine kinase activity (Cooper, 1990; Bishop, 1991). The MOS 
protein is a cytostatic factor (CSF) which arrests vertebrate eggs in the 
meiotic cycle (Sagata et al., 1989). The RAF protein is involved in a 
cytoplasmic kinase cascade and is activated by interaction with active RAS 
protein (Marshall, 1996). 
Another group of cytoplasmic oncogenes are the RAS genes (HRAS,  
KRAS and NRAS) which encode proteins of 21 kD located on the inner 
surface of the plasma membrane (Barbacid, 1987; McCormick, 1989). RAS 
proteins bind guanine nucleotides and have intrinsic GTPase avtivity. They 
also show structural  and funct ional  s imilar i t ies  to  the G-proteins .  The RAS 
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genes are activated by point mutations, preferentially occurring at codons 12, 
13 and 61 (Bos, 1988). Most mutations seem to result in a decrease in the 
GTPase activity and/or increase the rate of bound GDP for free GTP. 
Nuclear regulatory proteins. Oncogenes also encode proteins localized in 
the nucleus (Eisenman, 1989; Cooper, 1990). These proteins contain 
structural motifs such as helix-loop-helix, leucine zipper, zinc finger, and 
homeobox domains, indicating that they are involved in DNA-binding and 
transcriptional regulation (Bishop, 1991). Examples of such oncogenes are 
JUN, FOS, MYC, MYB, ETS, SKI, and REL. The products of t he JUN and FOS 
gene family are components of the AP-1 transcription factor. They can be 
activated as oncogenes simply by overexpression of the normal gene 
products. The MYC genes, in particular MYC and NMYC, are activated in a 
variety of human tumors as a consequence of chromosomal translocation 
(Burkitt's lymphoma) and gene amplification (neuroblastoma, lung cancer, 
breast cancer) (Cooper, 1990; Schwab and Amler, 1990; Rudduck et al., 1992). 
Recent studies have also shown that members of the ETS-family of 
transcription factors are frequently fused to the EWS gene in Ewing 
sarcomas (Kaneko et al., 1996). 
Tumor suppressor genes 
The tumor suppressor genes, sometimes also referred to as anti-
oncogenes, encode for growth-inhibitory proteins whose loss or inactivation 
is associated with tumor development (Hinds and Weinberg, 1994). 
Inactivation of these genes can occur through deletions or point mutations. 
Important evidence in support of the existence of genes with tumor-
suppressing activity comes from several independent lines of research 
(Knudson, 1985, 1987; Sager, 1985, 1989; Sandberg, 1990; Seizinger et al., 1991; 
Stanbridge, 1992): 1) somatic cell fusions between tumorigenic and non-
tumorigenic cells often result in a non-tumorigenic hybrid. When such 
hybrids give rise to tumors in animals this usually involves the loss of a 
specific chromosome from the non-tumorigenic cell, suggesting that this 
chromosome contains a suppressor gene; 2) there are a number of human 
tumors that characteristically show both cytogenetically and molecularly 
detectable deletions, e.g. deletions of 3p sequences in lung cancer and 
complete or partial loss of chromosome 22 in meningioma. These losses 
indicate the positions of putative tumor suppressor genes; 3) the findings of 
constitutional and/or tumor-associated deletions in patients with hereditary 
cancers, e.g. retinoblastoma and Wilms' tumor. 
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One of the best studied examples of hereditary cancers is the 
retinoblastoma. About 60% of retinoblastomas are sporadic cases with no 
family history of the disease, and with a single tumor in one eye. The 
remaining 40% of the cases are familial with bilateral tumors and often 
more than one independently derived tumor in one eye. In 1971, Knudson 
proposed a "two-hit" model for the development of retinoblastoma. He 
postulated that in the hereditary cases the first hit was a mutation of one 
allele in the germ line and that the second hit was a somatic mutation of the 
other allele. In the sporadic cases he proposed that both mutations were 
somatic. This model was later confirmed by the cloning of the RBI gene 
(Friend et al., 1986; Lee et al., 1987a, b) and the subsequent genetic studies of 
retinoblastoma families (cf. below). 
Compared to oncogenes, relatively few tumor suppressor genes have so 
far been cloned. Examples of su ch genes are the retinoblastoma gene (RBI), 
the Wilms' tumor gene (WT1), the TP53 gene, the familial adenomatosis 
polyposis coli gene (APC), the deleted in colorectal cancer gene (DCC) 
(Levine, 1993; Cho and Fearon, 1995), the breast cancer susceptibility type 1 
(BRCA1) and type 2 (BRCA2) genes (Hall et al., 1990; Wooster et al., 1994), 
and the neurofibromatosis type 1 (NF1) and type 2 (NF2) genes (Cawthon et 
al., 1990; Trofatter et al., 1993; Rouleau et al., 1993). In the following I will 
give a short description of some of these genes. 
The Retinoblastoma gene (R BI). The retinoblastoma locus was orignally 
mapped on the basis of cytogenetically visible deletions involving 
chromosome band 13ql4. Cloning of the RBI gene (Friend et al., 1986; Lee et 
al., 1987a, b) revealed that it encodes a 105 kDa nuclear phosphoprotein that 
is regulated by cell cycle dependent phosphorylation (Fig. 2). The protein is 
active in growth suppression by preventing transcriptional activation of 
several cell cycle regulatory genes. RBI is ubiquitously expressed. The gene 
is defective in all retinoblastomas as well as in a number of other cancers, 
including small cell lung carcinoma, bladder cancer, breast cancer, and 
osteosarcoma (secondary to retinoblastoma) (Marshall, 1991). 
The Wilms' tumor gene (WT1 ). Wilms' tumor (WT) is a rare childhood 
tumor of the kidney that is often seen together with different congenital 
malformations and mental retardation (WAGR syndrome). Similar to 
retinoblastomas, WT occur both in familial and sporadic forms. There are at 
least two loci on chromosome 11 associated with the hereditary forms of 
WT, one at llpl3 (WT1) and one at llpl5 (WT2). The WT1 gene is a 
member of t he early growth response gene family (EGR genes) (Call et al., 
1990). It encodes zinc finger proteins expressed in the developing kidney, 
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spleen, gonads, and the uterus (Aaronson, 1991; Levine, 1993). The WT1 
proteins act as transcription factors. Recently, the WT1 gene was shown to 
be fused to the EWS gene as a result of a t(ll;22) in desmoplastic small 
round cell tumors (Ladanyi and Gerald, 1994). 
The TP53 gene. TP53 is the most commonly mutated gene in human 
cancer. The gene, which maps to 17pl3.1, consists of 11 exons. It encodes a 
nuclear phosphoprotein that can act as a sequence-specific transcription 
factor. The protein is ubiquitously expressed, and has a key function in the 
cellular response to DNA damage (Levine, 1993; Haffner and Oren, 1995). 
Depending on the degree of d amage p53 may induce Gl arrest or apoptosis. 
Because of its important cellular functions TP53 has been named "The 
Guardian of the Genome". Most inactivating mutations in TP53 are found 
in the highly conserved exons 4 to 9 (Hollstein et al., 1991). Germ line 
mutations in TP53 are found in patients with the Li-Fraumeni syndrome. 
Patients with this syndrome run an increased risk of developing a variety of 
mesenchymal and epithelial neoplasms at multiple sites (Malkin et al., 
1990). 
The APC gene. Familial adenomatosis polyposis (FAP) is a cancer 
syndrome characterized by the presence of hundreds to thousands of colonic 
polyps which, in untreated individuals, leads to colorectal cancer (Fig. 1). 
The disease is caused by inactivating mutations in the APC gene located at 
chromosome 5q21. Almost all of the mutations, frameshift or base 
substitutions, are found in the 5' half of the coding sequence, leading to 
expression of truncated proteins. The wild type protein controls cell growth 
by regulation of cell adhesion, cytoskeletal anchoring and signalling. APC 
binds to and down-regulates ß-catenin, a protein functioning in the 
WG/WNT signalling pathway. Truncated APC proteins are still able to bind 
catenins, but have lost their ability to alter intracellular catenin distribution 
and to bind microtubules (Kinzler et al., 1991; Levine, 1993; Polakis, 1995). 
DNA repair genes 
DNA is the only macromolecule capable of being restored after damage. 
Complementary base pairing is the key feature in directing the repair of the 
original structure. DNA damage may be caused by a variety of factors, 
including environmental chemicals, UV-light, ionizing radiation, cosmic 
rays, X-rays as well as by depurination and deamination which frequently 
occurs in human cells (Singer and Berg, 1991; Fishel and Kolodner, 1995). In 
eukaryotic cells there are a number of mechanisms by which different DNA 
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lesions may be repaired. Mismatch repair, for example, recognizes normal 
nucleotides which are unpaired or paired with a non-complementary 
nucleotide. Several human mismatch repair genes, which are homologous 
to components in Saccharomyces cerevisiae have been identified. Germ line 
mutations in at least four such genes, MSH2, MLH1, PMS1, and PMS2, have 
recently been identified in the hereditary nonpolyposis colon cancer 
syndrome (HNPCC) (Fishel and Kolodner, 1995). Nucleotide and base 
excision repair recognizes chemically modified nucleotides and bases, or 
adjacent nucleotides fused to each other (Fishel and Kolodner, 1995). 
Patients with the autosomal recessive disease Xeroderma Pigmentosum 
(XP) are extremely sensitive to UV-light and develop a variety of skin 
cancers (Sancar, 1994). XP-patients can be divided into seven different 
complementation groups, XP-A to XP-G, each carrying a mutation in a 
different gene (Hanawalt, 1994). 
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TUMOR CYTOGENETICS 
Extensive cytogenetic studies of human cancers, particularly myelo- and 
lymphoproliferative disorders, have unequivocally confirmed Boveri's 
original prediction, and it is now well established that the occurrence of 
clonal, acquired chromosome changes is a characteristic feature of neoplastic 
cells (Sandberg, 1990; Heim and Mitelman, 1995). An impressive number of 
nonrandom chromosome abnormalities have been identified among the 
more than 22,000 cytogenetically analyzed neoplasms included in the latest 
edition of the "Catalog of Chromosome Aberrations in Cancer" by Mitelman 
and co-workers (Mitelman, 1994). However, only 27 % of these are solid 
tumors, the remaining 73% being hematologic disorders and lymphomas. 
The reason for this discrepancy can no doubt be attributed to the well-
known technical difficulties in analyzing solid tumors, and in particular 
carcinomas. In spite of the extensive literature on chromosome changes in 
human neoplasia, there is thus still a need for continued cytogenetic 
analysis of solid tumors. 
Chromosome abnormalities in tumors can be divided into two main 
categories, i.e. primary and secondary abnormalities. Primary abnormalities 
are tumor specific and are often found as the sole anomalies, suggesting that 
they are of pathogenetic importance. Secondary abnormalities are, in 
contrast, not related to the establishment of the tumor, but rather to the 
progression of the tumor. Secondary abnormalities might be non-random 
and have been shown to be of prognostic significance in certain neoplasms. 
The fact that chromosome changes are tumor specific makes them useful as 
diagnostic markers. 
Chromosome changes in malignant neoplasms 
One of the most well-known examples of a primary chromosome 
abnormality in man is the Philadelphia (Ph) chromosome in chronic 
myeloid leukemia (CML) resulting from a t(9;22)(q34;qll) (Nowell and 
Hungerford, 1960; Rowley, 1973). Molecular cloning of the translocation 
breakpoints revealed that the ABL oncogene at 9q34 was translocated to 
c h r o m o s o m e  2 2 q l l ,  w h e r e  i t  w a s  f u s e d  t o  a  n o v e l  g e n e  n a m e d  B  C R  
(Shtivelman et al., 1985). The BCR/ABL fusion gene has also been detected 
in Ph-negative CML as well as in cases with variant translocations where 
there is no cytogenetic evidence of involvement of chromosome 9 (van der 
Pias et al., 1991). Typical nonrandom, secondary chromosome changes in 
CML are an extra Ph chromosome, +8 and i(17q) (Sandberg, 1990). 
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The most well-known tumor-specific translocation in lymphomas is 
probably the t(8;14)(q24;q32) in Burkitt's lymphoma (Zech et a l, 1976). This 
translocation leads to the juxtaposition of the MYC gene at 8q24 to the 
immunoglobulin heavy chain locus at 14q32 (Dalla-Favera et al, 1987). The 
translocation leads to a head-to-head fusion of the two genes on 
chromosome 14. In the less frequent variant translocations t(2;8)(pl2;q24) 
and t(8;22)(q24;qll) the breakpoint is proximal to MYC. In these cases the 
lambda and kappa immunoglobulin light chain genes at 2pl2 and 22qll 
respectively are fused in a head-to-tail fashion to MYC on chromosome 8. 
The functional consequences of the three translocations seem to be very 
similar, i.e. overexpression of MYC (Croce, 1993; Heim and Mitelman, 1995). 
Bone and soft tissue sarcomas is a third group of neoplasms for which a 
reasonable number of tumors have been analyzed. The chromosomal 
pattern in many sarcomas is in several respects comparable to that in the 
leukemias. It is therefore not surprising that many of the tumor specific 
abnormalities seen in sarcomas are now routinely used as diagnostic 
markers in many laboratories. One such example is the t(ll;22)(q24;q22) 
which is typically seen in Ewing sarcoma, neuroepithelioma and Askin's 
tumor (Aurias et al, 1984; Turc-Carel et al, 1984; Meis-Kindblom et al, 1996). 
Other examples include the t(X;18)(pll;qll) found in both mono- and 
biphasic synovial sarcomas (Turc-Carel et al, 1986a, 1987), the t(2;13)(q37;ql4) 
in alveolar rhabdomyosarcoma (Seidal et al, 1982; Turc-Carel et al, 1986b), 
the t(12;16)(ql3;pll) in myxoid liposarcoma (Turc-Carel et a l., 1986c), the 
t(12;22)(ql3;q22) in clear-cell sarcoma of tendon s and aponeuroses (Bridge et 
al, 1990; Stenman et a l, 1992b), the t(9;22)(q22;ql2) in extraskeletal myxoid 
chondrosarcomas (Hinrichs et al, 1985; Stenman et al, 1995), and the 
t(ll;22)(pl3;ql2) in desmoplastic small round cell tumors (Sawyer et al, 1992; 
Shen et al, 1992). However, it should also be mentioned that there are 
several types of sarcomas, including osteosarcomas and chondrosarcomas, 
for which no specific abnormalities have so far been identified. 
Carcinomas are cytogenetically both more complex and heterogeneous 
than many other neoplasms. So far, very few recurrent abnormalities have 
been identified. In small cell lung cancer for instance, an interstitial deletion 
del(3)(pl4p23) is frequently found (Whang-Peng et al, 1982), and in renal 
cell carcinomas terminal deletions with breakpoints at 3pl3 or distal to this 
band or a der(3)t(3;5)(pl3;q22) are recurrent (Kovacs et al, 1993). Subsets of 
breast carcinomas show trisomy 8 or del(3)(pl2pl4), sometimes as the sole 
anomalies (Pandis et al, 1995; Bullerdiek et al, 1993a), and among 
malignant salivary gland tumors a recurrent t(6;9)(q22~24;pl3-23) has been 
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found in adenoid cystic carcinomas (Nordkvist et al., 1994), and a 
t(ll;19)(ql4-21;pll) in mucoepidermoid carcinomas (Nordkvist et al., 1995). 
Chromosome changes in benign tumors 
Studies during the last two decades have demonstrated unequivocally 
that chromosome abnormalities are a characteristic feature not only of 
malignant tumors but also of benign tumors. For several benign tumor 
types, such as meningiomas, pleomorphic adenomas, lipomas, and uterine 
leiomyomas, extensive cytogenetic data are now available (Mitelman, 1994). 
The meningioma, a tumor originating from the meningeal coverings of the 
brain, was the first benign tumor reported to have a characteristic 
chromosome abnormality, i.e. complete or partial monosomy 22 (Mark et 
al., 1972; Zankl and Zang, 1972). Eight years later, Mark and co-workers 
(Mark et al., 1980) reported on a second type of benign tumor characterized 
by specific chromosome abnormalities, namely pleomorphic adenomas of 
the salivary glands. In the original report they described three cases with a 
t(3;8)(p21;ql2) or a variant thereof. Later studies have shown that this is the 
most frequent abnormality found in these tumors (Sandros et al., 1990; 
Bullerdiek et al., 1993b), and this translocation is also the subject of the 
present thesis. Further details of the chromosomal pattern in pleomorphic 
adenomas will be presented below. 
Subsequent studies from several independent groups have revealed that 
lipomas and uterine leiomyomas also display specific chromosome 
abnormalities. About 50-80% of the lipomas are cytogenetically abnormal 
(reviewed by Sreekantaiah et al., 1991; Mandahl et al., 1994). At least five 
cytogenetic subgroups have been distinguished: (1) lipomas with 
translocations of 12ql3-14, most common in the form of a t(3;12)(q27-28;ql3-
15); (2) lipomas with rearrangements of 6 p; (3) lipomas with rearrangements 
of 13q; (4) lipomas with ring chromosomes (commonly found in atypical 
lipomas); and (5) lipomas with sporadic rearrangements. It should be 
pointed out that there is also an overlap between several subgroups 
(Mandahl et ah, 1994). In uterine leiomyomas abnormal karyotypes have 
been reported in 20-50% of the cases (Mark et al., 1990; Nilbert and Heim, 
1990; Sreekantaiah and Sandberg, 1991). About 20% of these have a 
t(12;14)(ql4-15;q23). Other non-random changes are deletions of 7q, mostly a 
del(7)(q21.2;q31.2), rearrangements of 6pl2-21, trisomy 12, and various 
structural rearrangements of l p, 2p, and 13q. 
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Clinical, histopathological and cytogenetic aspects of pleomorphic adenomas 
Pleomorphic adenomas (previously also designated mixed tumors) are 
painless, slow-growing benign tumors originating from the major and 
minor salivary glands. It is the most common type of salivary gland 
neoplasm and accounts for about half of all cases. Over 60% of the tumors 
are found in the parotid gland. Pleomorphic adenomas are usually 
diagnosed in patients in the age range 30 to 50 years, but may develop at 
almost any age. They are more common in females, with male-to-female 
ratios varying from 1:3 to 1:4 (Waldron, 1991). The tumors, which are 
usually encapsulated, are mainly composed of epithelial and myoepithelial 
cells forming a variety of patterns in a matrix of mucoid, myxoid, 
chondroid, and sometimes even osteoid tissue. Typically, they show a wide 
morphologic spectrum, some tumors being principally myxoid, while others 
are highly cellular. The epithelial cells may form ducts, nests or solid sheets 
of cells. Immunocytochemically, the myoepithelial cells stain positive for 
cytokeratin, S-100 protein, glial fibrillary acidic protein, actin, and vimetin. 
Ductal epithelial cells and solid cellular nests are strongly immunoreactive 
for cytokeratin. Pleomorphic adenomas are treated by surgical excision. If 
radically removed the prognosis is excellent. Benign pleomorphic adenomas 
rarely undergo malignant transformation. In the AFIP series of 326 
carcinoma ex pleomorphic adenoma cases (Gnepp and Wenig, 1991), these 
represented 4.5 % of all pleomorphic adenomas. Carcinoma ex pleomorphic 
adenoma is a very aggressive tumor, and in cases in which the capsule has 
been penetrated the prognosis is poor . 
Chromosomal aberrations in pleomorphic adenomas were first reported 
by Scappaticci et al. in 1973, but in the absence of chromosome banding, they 
could not identify any specific abnormalities. Today, about 500 pleomorphic 
adenomas have been cytogenetically analyzed, mainly by two independent 
laboratories in Sweden and in Germany (Sandros et al., 1990; Bullerdiek et 
al., 1993b; Mark et al., 1997). These studies have revealed that about 20 to 50 
% of the adenomas have apparently normal karyotypes. The remaining 
cases, which are all cytogenetically abnormal, can be divided into three 
major subgroups. 
The first and largest subgroup comprise cases with rearrangements 
involving band 8ql2. The most common abnormality in this subgroup is a 
t(3;8)(p21;ql2). This was in fact the first tumor specific translocation 
identified in a benign human tumor (Mark et al., 1980). In addition to the 
t(3;8) there are also a large number of variant translocations in which the 
8ql2->qter segment has been translocated onto a wide range of other 
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chromosomal bands. It should also be pointed out that there are two minor 
clusters of breakpoints at 8pl2-23 and 8q21-22. Finally, there are a few cases 
on record with trisomy 8. 
The second cytogenetic subgroup of adenomas comprises cases with 
rearrangements involving 12ql3-15. The preferential abnormality in this 
subgroup is a t(9;12)(pl2-22;ql3-15) or an ins(9;12) with similar breakpoints 
(Stenman et al., 1994; Geurts et al., 1997b). Similar to the first subgroup there 
are also variant translocations involving different translocation partners. 
Two additional, minor clusters of breakpoints located at 12pl3 and 12q24 are, 
together with 12ql3-15, sometimes involved in inversions. In addition, 
there are a few known adenomas with interstitial deletions of 12ql3-15. One 
of these cases contained double-minute chromosomes (dmin), and it was 
suggested that the dmin originated from the deleted 12q segment (Mark et 
al., 1982). This adenoma was the first benign tumor reported to contain 
dmin. 
The third and smallest subgroup of adenomas comprises cases without 
the involvement of 3p21, 8ql2 or 12ql3-15. These cases have instead 
sporadic numerical and/or structural rearrangements affecting other 
chromosomes or chromosome segments. 
There are thus three preferential chromosome regions, 3p21, 8ql2, and 
12ql3-15, that are repeatedly rearranged in pleomorphic adenomas. The fact 
that these are often found as the sole karyotypic anomalies indicates that 
they are primary cytogenetic events of pathogenetic importance. Secondary 
chromosome changes, including dicentrics, rings and dmin, have been 
found in about one-third of the cases with clonal changes. So far, no non-
random secondary abnormalities have been recognized. Interestingly, 
Bullerdiek and co-workers (Bullerdiek et al., 1993b) have been able to 
correlate the karyotypes of a large number of adenomas with different 
clinicopathological parameters. They found that tumors with 8ql2 
abnormalities generally occurred in younger patients compared with those 
with normal karotypes. In addition, they found that tumors with normal 
karotypes were often more stroma rich than were the tumors with 8ql2 
abnormalities. 
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MOLECULAR BASIS OF CHROMOSOME ABNORMALITIES 
IN SOLID TUMORS 
Compared to leukemias and lymphomas little is known about the 
molecular basis of chromosome abnormalities in solid tumors. Most of our 
knowledge in this field derives from recent studies of certain types of bone 
and soft tissue sarcomas. The perhaps most well-known translocations for 
which the affected genes have been identified are summarized in Table 1. 
Table 1. Summary of recurrent translocations and the genes involved in solid tumors. 
Tumor type Chromosome 
rearrangement 
Genes 
involved 
Reference 
Ewing sarcoma t(l I;22)(q24;ql2) 
t(21;22)(q22;ql2) 
t(7;22)(p22;ql2) 
t(17;22)(ql2;ql2) 
EWS/FLI1 
EWS/ERG 
EWS/ETVl 
EWS/EIAF 
Zucman et al., 1992 
Sorensen et al., 1994 
Jeon et al., 1995 
Kaneco et al., 1996 
Clear cell sarcoma t( 12;22)(q 13 ;q 12) EWS/ATF1 Zucman et al, 1993 
Extra skeletal myxoid 
chondrosarcoma 
t(9;22)(q22;ql2) EWS/TEC Labelle et al., 1995 
Desmoplastic small 
round cell tumor 
t(l I;22)(pl3;ql2) EWS/WT1 Ladanyi and Gerald, 1994 
Myxoid liposarcoma t(12;16)(ql3;pl 1) 
t(12;22)(ql3;ql2) 
FUS/CHOP 
EWS/CHOP 
Rabbitts et al., 1993 
Crozat et al., 1993 
Panagopoulos et al.. 1996 
Dermatofibrosarcoma 
protuberans 
t( 17 ;22)(q22;q 13) COL1A17PDGFB Simon M-P et al., 1997 
Alveolar rhabdomyo 
sarcoma 
1(2; 13)(q35:ql4) 
t(l;13)(p36;ql4) 
PAX3/FKHR 
PAX7/FKHR 
Galili et al., 1993 
Shapiro et al., 1993 
Davis et al., 1994 
Synovial sarcoma t(X;18)(pl 1.2;ql 1.2) 
t(X;18)(pl 1.2;ql 1.2) 
SYT/SSX1 
SYT/SSX2 
Clark et al. , 1994 
Crew et al., 1995 
Lipoma t(3;12)(q27-28;ql3-15) HMGIC/LPP Petit et al., 1996 
Uterine leiomyoma inv(12)(ql5;q24.1) HMGIC/ALDH2 Kazmierczak et al., 1995 
Pleomorphic adenoma t(3p;10p;12q) 
ins(9;12)(p23;ql2ql5) 
HMGIC/FHIT 
HMGIC/NF1B 
Geurts et al., 1997a 
Geurts et al., 1997b 
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Of these, the t(ll;22)(q24;ql2) found in Ewing sarcoma and peripheral 
primitive neuroectodermal tumor (PNET) is the prototype. Extensive 
studies mainly from Gilles Thomas and his co-workers, have shown that 
the gene affected on chromosome 22 in a number of sarcomas with 
translocation breakpoints at 22ql2 is the EWS gene, which encodes an RNA-
binding protein. In the t(ll;22) translocation EWS is fused to the FLU gene at 
llq24. FLI1 encodes a DNA-binding protein belonging to the ETS-family of 
transcription factors. In the hybrid transcripts produced by the der(22) the 
RNA-binding domain of EWS is replaced by the DNA-binding domain of 
FLI1. Similarly, in three variant translocations other members of the ETS-
family, ERG, ETV1, and EIAF, are fused to EWS. These translocations lead to 
constitutive expression of chimeric EWS proteins with presumed 
transforming properties. Indeed, it  was recently shown that the EWS/FL11 
fusion gene can transform NIH3T3 cells (May et al., 1993). Collectively, these 
findings show that fusion of EWS to different members of the ETS-gene 
family results in very similar disease phenotypes, i.e. Ewing sarcoma or 
PNET (Sorensen et al., 1994; Jeon et al., 1995). 
Recent studies have demonstrated that EWS is also involved in several 
other sarcomas with translocations affecting chromosome band 22ql2, such 
as clear cell sarcoma, desmoplastic small round cell tumor, and extra skeletal 
myxoid chondrosarcoma (Table 1). However, in these tumors EWS is fused 
to other transcription factors not belonging to the ETS-family. The 
molecular consequences of these translocations are very similar, i.e. they 
lead to fusion genes where the N-terminal RNA-binding domain of EWS is 
substituted by the DNA-binding domains of different transcription factors. 
Another tumor type with a comparable translocation is myxoid 
liposarcoma (MLS). In the MLS-specific t(12;16)(ql3;pll) the CHOP gene (also 
called GADD153) on chromosome 12 is fused to FUS (also called TLS) on 
chromosome 16 (Crozat et al., 1993; Rabbitts et al., 1993). CHOP codes for a 
dominant negative transcription factor, and FUS for an RNA-binding 
protein with homology to EWS. It has been shown that the TLS-CHOP 
fusion protein can function as a transcriptional activator in vitro (Zinszner 
et al., 1994). Recent studies have also shown that the N-terminal domain of 
EWS, both in vitro and in vivo, can replace the TLS part of TLS-CHOP 
(Zinszner et a l., 1994; Panagopoulos et al. , 1996). 
A common theme for several sarcoma associated translocations thus 
appears to be the fusion of genes containing RNA-binding domains (e.g. 
EWS or TLS) with transcription factor genes containing DNA-binding 
domains (e.g. FLU, ERG, ATF1, WT1, or CHOP). The target specificity of the 
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transcriptional activation seems to be determined by the gene supplying the 
DNA-binding domain, whereas the transactivation potential and expression 
level seem to be determined by the gene supplying the N-terminal domain 
and the promoter region (Ladanyi, 1995). 
As mentioned previously, there are several benign tumor types with 
consistent rearrangements of 12ql3-15, including pleomorphic adenomas, 
lipomas, uterine leiomyomas, pulmonary chondroid hamartomas, 
endometrial polyps, aggressive angiomyxomas, and hamartomas and 
fibroadenomas of the breast (Mitelman, 1994). Recently, two groups 
identified the HMGIC gene at 12ql5 as the target gene in these tumor types 
(Ashar et al., 1995; Schoenmakers et al., 1995). Subsequent studies have 
demonstrated that HMGIC is in fact involved in all of the above-mentioned 
tumor types (Bol et al., 1996; Kazmierczak et al., 1996; Staats et al., 1996). 
HMGIC belongs to the high mobility group (HMG) protein gene family, 
which comprises proteins that are nonhistone components of chromatin 
(Grosschedl et al., 1994). The HMGI-C protein binds in the minor groove of 
DNA and is thought to function as an architectural factor in the nuclear 
scaffold (Saitoh and Laemmeli, 1994). It is also suggested to be of i mportance 
in the assembly of stereospecific transcriptional complexes (Tjian and 
Maniatis, 1994; Giancotti et at., 1991). Interestingly, mice in which both 
Hmgic alle les have been knocked out  show the pygmy phenotype (Zhou et  
al, 1995). 
Most breakpoints in HMGIC are located within the third large intron, 
resulting in the separation of the three predicted DNA-binding domains 
(exons 1 to 3) in the amino-terminal region from the acidic, carboxy-
terminal domain. So far, four fusion partner genes of HMGIC have been 
identified, i.e. LPP, ALDH2, FHIT, and NF1B (Table 1). Interestingly, the 
latter two have been identified in pleomorphic adenomas; FHIT in an 
adenoma with a complex t(3p;10p;12q) and NFIB in two adenomas with 
ins(9;12). In the first case, the first three exons of HMGIC, encoding the three 
AT-hook domains, were fused to exons 9 and 10 of the FHIT gene, which 
encodes the last 31 carboxy-terminal amino acids. In the latter case, the first 
three or four exons of HMGIC were fused to exon 12 of NFIB. Since no 
common functional domain has been identified so far among the known 
translocation partners, the critical event seems to be the separation of the 
DNA-binding domains from the acidic carboxy-terminal tail of HMGI-C 
(Geurts 1997a). 
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THE HUMAN GENOME PROJECT 
The human genome project (HUGO) is an international research project 
the purpose of which is to map and sequence the entire human genome. It 
involves a number of large research institutions, mainly in the United 
States, Europe and Japan. The project, which is expected to cost $3 billion, 
was initiated in the United States in 1988 with funding from the National 
Institute of Health (NIH) and the Department of Energy (DOE). In 1989 the 
National Center for Human Genome Research division of the NIH was 
established. The goals of the project are to construct genetic and physical 
maps, to determine the complete sequence of the human DNA and to study 
the genomes of nonhuman model organisms. To accomplish these goals the 
development of new technology will be necessary, in particular 
improvements in the efficiency of DNA sequencing. The extensive 
knowledge of the human genome and its expected 100,000 genes that will 
come from the genome project will have an enormous impact on our 
understanding of human biology and diseases. It will profoundly alter our 
approach to medical care by shifting our focus from treatment of established 
diseases to disease prevention (Guyer and Collins, 1993; Olson, 1993; 
Hoffman, 1994). However, these new developments also raise a number of 
important ethical, legal, and social questions that need to be resolved. 
Genetic maps 
Genetic linkage maps are based on the frequency at which polymorphic 
markers are coinherited. During meiosis, genetic recombination or crossing 
over lead to separation of markers that were on the same chromosome in 
the parents. Closely linked markers are coinherited more often than distant 
ones. A major breakthrough that made it possible to construct human 
linkage maps was the discovery of minor DNA sequence variations 
(polymorphisms), which normally occur, and constitute the basis for 
human variability. Polymorphisms, such as microsatellite repeats and CA 
repeats, can be easily detected using the polymerase chain reaction (PCR). 
Much of the initial work on the construction of genetic maps of the entire 
human genome was done at the French institute Généthon, established and 
funded by the French muscular dystrophy association (Dib et ai, 1996). The 
first linkage map of the entire human genome was published in 1987 
(Donis-Keller et al., 1987). The latest map, published last year, consists of 
5,264 microsatellites with an average spacing of 1.6 cM (Dib et al., 1996). 
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These maps greatly facilitate the localization of disease genes through 
family-based genetic linkage studies. 
Physical maps 
On physical maps the real distances between individual genes and 
markers are determined. The resolution of such maps is higher compared 
with linkage maps. The goal of this part of the genome project is to produce 
high resolution maps consisting of cloned DNA fragments that cover the 
entire genome and to develop unique PCR primer sets that recognize sites 
(sequence-tagged sites - STSs) along the entire genome (Guyer and Collins, 
1993; Hoffman, 1994). The most useful types of physical maps are those that 
consist of cloned, overlapping DNA segments, so-called contigs. Important 
tools for the construction of contigs are the YAC and mega-YAC libraries 
developed by the Centre d'Etude du Polymorphisme Humain (CEPH) in 
France. YACs or yeast artificial chromosomes are vectors that allow large 
DNA fragments to be cloned as an additional chromosome into 
Saccharomyces cerevisiae.. The first physical maps of entire human 
chromosomes were published for the long arm of chromosome 21 and for 
the Y chromosome (Chumakov et al., 1992; Foote et al., 1992). Recently a 
YAC contig map covering about 75% of the entire human genome was 
described (Chumakov et al., 1995). The map consists of 225 contigs with an 
average size of about 10 megabases. YAC contigs with varying coverage of 
the human genome are now available for all human chromosomes through 
the world wide web. Physical maps are essential tools in the identification of 
disease genes. Once such a gene has been localized on the genetic map the 
corresponding YAC clones from the physical map can be easily isolated and 
used in the identification of the gene in question. 
Positional cloning 
Isolation or cloning of a gene can be done either by positional cloning 
(previously also called reverse genetics) or functional cloning. In the case of 
functional cloning the gene product and/or the function of the gene must be 
known in advance. The gene is thus cloned before it is mapped. Positional 
cloning, on the other hand, begins with mapping the gene to a specific 
location on a chromosome. In this case the function of the gene is 
determined after it is cloned (Guyer and Collin, 1993). Positional cloning 
strategies rely on physical mapping information for the chromosome region 
of interest. During the past few years, a number of genes involved in 
hereditary cancer syndromes, such as the Neurofibromatosis type 1 and type 
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2 genes, the von Hippel-Lindau disease gene, and the Wilms' tumor gene, 
have been identified by positional cloning (Cawthon et al., 1990; Call et al., 
1990; Trofatter et al., 1993; Rouleau et al., 1993; Latif et al., 1993; Kley et al, 
1995). This approach has also proved to be very useful in the identification 
of genes involved in tumor specific chromosome rearrangements (Zucman 
et al., 1992; Schoenmakers et al., 1995). In such cases the chromosome region 
of interest has already been identified, and the chromosomal breakpoints 
can be mapped by FISH (fluorescence in situ hybridization) on tumor 
chromosomes using YACs derived from the region. The region 
encompassing the breakpoint is identified by chromosome walking . A YAC 
contig based on STS-content mapping is constructed, and YACs from this 
contig are mapped by FISH with the purpose of identifying a YAC spanning 
the breakpoint. This YAC is then further characterized and used to identify 
the relevant gene. 
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AIM OF THE STUDY 
The primary goal of this thesis was to identify the genes involved in the 
recurrent t(3;8)(p21;ql2) translocation in pleomorphic adenomas using a 
positional cloning approach. 
MATERIALS AND METHODS 
All studies in this thesis were performed on cultured cells, chromosome 
preparations, DNA and/or RNA, derived from primary tumor tissue not 
required for histopathological diagnosis. From each specimen analyzed, a 
portion was examined histopathologically to assess the tumor content. All 
12 tumors used were benign pleomorphic adenomas. They all had a 
translocation breakpoint at 8ql2, either in the form of the classic 
t(3;8)(p21;ql2) or a variant translocation. From most tumors, metaphases 
stored in frozen fixative, fresh frozen tumor tissue, as well as frozen 
cultured cells from the same tumor ,were available. All physical mapping 
experiments were performed on metaphases obtained from primary 
cultures. 
The different methods used in this thesis are described in detail in Papers 
I - IV or, in some cases, in references therein. Hence these will not be 
commented on further here. 
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RESULTS AND DISCUSSION 
Identification of a YAC-clone spanning the 8ql2 translocation breakpoint 
(Paper I) 
As a starting point for the positional cloning effort to isolate the gene 
affected by the translocations involving 8ql2 in pleomorphic adenomas, we 
isolated a YAC-clone (ICFRy900G10157) corresponding to the MOS proto-
oncogene located at 8qll-12. This YAC also contained the proto-oncogene 
LYN. The rationale for selecting MOS as a starting point was an earlier 
report showing that MOS and its flanking sequences were mutated in two 
pleomorphic adenomas with 8ql2 abnormalities (Stenman et al., 1991a). 
FISH mapping of this YAC, together with a phage clone containing a third 
candidate gene CEBPD (CEBPD belongs to a family of leucine zipper 
transcription factors), on chromosomes from two adenomas with 
t(3;8)(p21;ql2) revealed that all three genes were proximal to the breakpoints. 
These observations suggest that none of these genes is involved in the 8ql2 
translocations and that the target gene is a novel gene. 
Chromosome band 8ql2 is, according to radiation hybrid mapping data, 
flanked by the markers D8S165 and MOS proximally and by D8S260 distally 
(Sapru et al., 1994). To sublocalize the breakpoints within this region we 
isolated a number of YACs corresponding to the genetic markers D8S260, 
D 8 S 1 0 8 ,  a n d  D8 S 1 6 6  ( t h e  l a t t e r  t w o  a r e  l o c a t e d  a b o u t  1  M b  di s t a l  t o  M O S ) .  
FISH mapping of these revealed that they were all distal to the breakpoints 
in both adenomas, demonstrating that the breakpoints are located within a 1 
Mb region flanked by MOS and D8S166. 
To fine map the breakpoints we initiated a chromosome walk starting 
from MOS. Two YACs corresponding to D8S285, which maps less than 100 
kb distal to MOS, were isolated. STS-content mapping of these revealed that 
YAC 166F4 also contained MOS and LYN, and that YAC 935E9 contained 
LYN, PENK and D8S165 but had an internal deletion of MOS. FISH analysis 
using these YACs demonstrated that they spanned the t(3;8) breakpoints. 
YAC 166F4, which contains MOS, LYN and D8S285, covers about 700 kb of 
genomic DNA. The smaller ICRF YAC, which contains MOS and LYN, but 
not D8S285, maps proximal to the breakpoint, indicating that the 
breakpoints are located between MOS and the distal part of YAC 166F4, a 
region estimated to be about 300 to 400 kb. 
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Mapping of the 8ql2 translocation breakpoint to a 40-kb region (Paper II) 
In this paper we describe the physical mapping of the breakpoints in a 
pleomorphic adenoma (CG682) with an insertion of a 3p segment into 8ql2, 
i.e. a rearrangement similar to the t(3;8)(p21;ql2). Based on G-banding and 
FISH, the karyotype of this tumor was 46,XX,der(3)del(3)(p23-
>24)del(3)(p21.3pl4.1), der(8)dir ins(8;3)(ql2;p21.3 pl4.1). To further map the 
8ql2 breakpoint we isolated cosmids from a chromosome 8-specific library 
(Wood et al., 1992) using STSs corresponding to markers, genes and YAC-
ends mapping within YAC 166F4, which we previously showed spanned the 
breakpoint in adenomas with the classic t(3;8) (Paper I). FISH mapping of 
these cosmids revealed that the 8ql2 insertion breakpoint was located 
within a 300-kb region flanked by MOS and a new STS CH129. A cosmid 
derived from this region, CEM23, was shown to span the breakpoint. The 
clustering of the 8ql2 breakpoints to a limited region in tumors with the 
recurrent t(3;8) (Paper I), as well as in variants thereof, indicate that a 
common molecular mechanism underlies the different 3;8 rearrangements. 
Our mapping of the breakpoint in the present case to a 40-kb region will 
facilitate the search for the 8ql2 gene. 
The FHIT gene at 3pl4.2 was recently shown to span the hereditary renal 
cell carcinoma associated t(3;8)(pl4.2;q24) breakpoint and the FRA3B fragile 
site (Ohta et al., 1996). Using a YAC containing FHIT we could show by FISH 
that FHIT was transposed to the der(8) but not disrupted by the 3;8-
rearrangement.  RT-PCR analysis showed only the normal-sized 709-bp FHIT 
fragment, indicating that FHIT is not affected in this case. This was also 
shown to be the case in adenomas with t(3;8).  FISH analysis using the FHIT 
YAC and a chromosome 8 painting probe confirmed the orientation of the 
inserted 3p-segment into the der(8). Interestingly, we recently reported a 
pleomorphic adenoma with a complex rearrangement involving 
chromosomes 3, 10 and 12 in which the first three exons of HMGIC were 
fused to exons 9 and 10 of FH IT (Geurts et al., 1997a). 
Construction of a YAC contig and physical map covering the 8ql2 
translocation breakpoint cluster region (Paper III) 
According to previous mapping data, band 8ql2 is flanked by the markers 
D8S165/D8S285 proximally and by D8S260 distally (Sapru et al., 1994). YACs 
corresponding to these markers were used for initiating the walk towards 
the 8ql2 breakpoints. We thus started from D8S285 and constructed a 2 Mb 
YAC contig covering the centromeric part of band 8ql2, and from D8S260 
and generated a 5 Mb contig covering the telomeric part of 8 ql2. These two 
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non-overlapping contigs cover about 75% of b and 8ql2. Since the majority of 
breakpoints were found in the centromeric contig our research was focused 
on this. 
The centromeric contig covers approximately 2 Mb of genomic DNA and 
consists of 34 overlapping YAC clones, with insert sizes between 169 kb and 
1660 kb. It is tagged by 31 markers with an average spacing of 65 kb. Initially, 
we walked bidirectionally and this allowed us to link this contig to an 
existing chromosome 8qll YAC contig (MIT contigs WC8.7 and WC-157). 
All markers and genes that were or became publicly available during our 
work were STS content mapped in the contig and those found positive were 
sublocalized by (primer) hybridization to YAC Southern blots. Three genes, 
MOS, LYN and PENK, and three expressed sequence tags (ESTs) could be 
p o s i t i o n e d  i n  t h e  c o n t i g .  O n e  E S T  c o r r e s p o nd e d  t o  L YN ,  o n e  t o  P L A G 1  
(Paper IV), and one did not resemble any currently known gene. A 
restriction map generated with rare-cutter enzymes revealed at least 7 
p u t a t i ve  C p G  i s l a n d s .  F o u r  o f  t h e s e  c o r r e s p on d  t o  k n o w n  g e n e s  ( M O S ,  L Y N ,  
PENK, and PLAG1), while the others might represent the 5' end of novel 
genes. 
The starting point for the telomeric contig was D8S260, for which two 
megaYACs were isolated. An STS (CH31) corresponding to the distal end of 
one of these was shown to be present in two YACs containing D8S510, 
which links our contig to an 8ql3 specific contig (Doerflinger et al., 1995). 
The telomeric contig consists of 23 megaYACs and covers about 5 Mb of 
genomic DNA. One gene, CYP7, was shown to reside within the contig. The 
fact that we have only been able to identify and map five genes in the two 
contigs, which together cover about 75 % of b and 8ql2, is consistent with the 
view that Giemsa-positive bands are chromosome regions rather low in 
G+C content and poor in genes (Craig and Bickmore, 1993). 
Identification of a major breakpoint cluster region in 8ql2 (Paper III) 
In previous studies we have shown that YAC 166F4 spans the breakpoint 
in two adenomas with t(3;8)(p21;ql2) (Paper I) and that a cosmid clone 
mapping within this YAC covers the breakpoint in an adenoma with an 
ins(8;3) (Paper II). To extend these observations we have now analyzed five 
additional adenomas with different 8ql2 abnormalities (for details of their 
karyotypes see Table 1 in Paper III). FISH analysis of these cases revealed that 
three of them had a breakpoint within YAC 166F4, and two cases had a 
breakpoint proximal to this YAC (cf. below). Fine mapping of these 
breakpoints using cosmids containing MOS (CEM1) and STS EM156 (CEM23) 
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revealed that the breakpoints in six of eight tumors tested were in a 300-kb 
region flanked by these two cosmids. The fact that both tumors with the 
recurrent t(3;8)(p21;ql2) and those with 8ql2 translocations and other 
translocation partners have breakpoints within the 300-kb region, indicate 
that this is the major breakpoint cluster region in pleomorphic adenomas 
with 8ql2 abnormalities. 
Two of the eight tumors tested had breakpoints proximal to MOS. In one 
case the breakpoint was mapped between MOS and YAC 898G12, and in the 
other case it was found to reside within YAC 943G4 (containing the X RCC7 
gene), which maps at least 2 Mb centromeric to MOS. Since these two 
breakpoints are clearly different from those located in the 300 kb breakpoint 
region, it is unlikely that they affect the same gene. Interestingly, we have 
recently obtained molecular data suggesting the presence of an additional 
breakpoint region distal to our telomeric contig. Based on FISH we have 
estimated that these breakpoints are 15 to 20 cM telomeric to the 8ql2 
breakpoint cluster region. Collectively, our findings thus suggest that there 
are several genes in the proximal part of 8 q that are affected by chromosome 
rearrangements in pleomorphic adenomas. 
Identification and characterization of the PLAG1 gene (Paper IV) 
In this paper we show that PLAG1 (Pleomorphic Adenoma Gene 1) is the 
target gene affected by the 8ql2 translocations in pleomorphic adenomas. In 
previous studies (Paper III) w e identified a 300-kb breakpoint cluster region 
between MOS and STS EM156. To fine map this region and eventually 
identify the PLAG1 gene we developed a contig consisting of 27 cosmids and 
2 phage clones. The contig covers 300-kb of genomic DNA. By FISH we could 
show that two cosmids, 149G12 and 4H6, spanned the 8ql2 breakpoints in 
two adenomas. BLAST searches of new STSs from the contig revealed that 
the right end of YAC 143D5 (STS CH283) displayed sequence identity with a 
publicly available EST. In Northern blot analysis using this EST as a probe, a 
7.5 kb transcript was detected, representing the putative PLAG1 gene. This 
transcript was detected in several fetal tissues, including lung, liver, kidney, 
and placenta (low levels), but not in any of the adult tissues examined, 
salivary gland tissue included. 
Cloning and analysis of the PLAG1 cDNA showed that it contains an 
open reading frame (ORF) of 1500 bp, starting with the ATG at position 481-
483. An in frame stop codon (TAG) is present 9 nucleotides upstream of this 
ATG. The composite cDNA (7313 nucleotides) of PL AGI has the coding 
capacity for a protein with a molecular weight of 56 kD. The deduced amino 
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acid sequence of the PLAG1 protein reveals seven canonical C2H2 zinc finger 
domains in the N-terminal region and a serine-rich, non-finger region 
representing the C terminus. There are two potential nuclear localization 
signals in the N-terminal region. Strictly speaking, the deduced PLAG1 
protein is not a Krüppel zinc finger protein, since it does not contain the 
characteristic H/C linker between the zinc fingers (Beliefroid et al., 1989). 
Collectively, the structural features suggest that the PLAG1 protein is a 
novel member of the large zinc finger gene family. The PLAG1 sequence is 
not homologous to any known zinc finger protein, although studies of 
anonymous ESTs have indicated that there is at least one closely related 
human gene, tentatively designated PLAG2. Cloning and characterization of 
this gene is now in progress. 
Apart from transcriptional modulation and control of RNA metabolism, 
cromatin packaging might also constitute an important activity through 
which zinc finger proteins exert their regulatory roles (El-Baradi and Pieler, 
1991). In this context it should be noted that the presumed role of HMGI-C is 
also to be found in chromatin modelling (Wolffe, 1994). The mammalian 
genome contains a large number of zinc finger genes (Bellefroid et al., 1989), 
and the number of such genes implicated in cancer is growing steadily. For 
example, mutations within the zinc finger gene WT1 predispose to Wilms' 
tumor (Haber et al., 1990). Furthermore, in desmoplastic small round cell 
tumors, WT1 is fused to EWS as the result of a t(ll;22)(pl3;ql2) (Ladanyi and 
Gerald, 1994), and in acute promyelocytic leukemia, a fusion occurs between 
the ret ino ic  acid recepto r-a  locus and a  Kri ippel- l ike z inc f inger  gene PML 
due to a t(15;17)(q22;qll-21), or to the zinc finger gene PLZF, due to a variant 
t(ll;17)(q23;q21) (de Thé et al., 1991; Chen et al., 1993). Similarly, in non-
Hodgkin's lymphoma, LAZ3/BCL6, a gene encoding a protein with seven 
zinc fingers, is rearranged by recurrent translocations involving 3q27 
(Kerckaert et al., 1993; Ye et al., 1993). 
Genomic organization of the PLAG1 gene (Paper IV) 
Comparison of transcribed and genomic sequences of the PLAG1 gene 
revealed that it contains 5 exons. The transcriptional orientation of the gene 
is directed towards the centromere. The first three exons are non-coding, the 
fourth exon contains the translation start site (ATG), and the N terminus of 
the protein, including one complete zinc finger. The second finger is split by 
intron 4 and continues into exon 5, which contains the remaining part of 
the ORF and the long 3'-UTR (5533 bp). Based on our YAC and cosmid 
maps, the PLAG1 locus spans about 35 kb, with a large intron (approximately 
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25 kb) between exon 1 and exon 2. RACE analysis has revealed two 
alternatively spliced mRNAs, differing from each other by the presence or 
absence of the non-coding exon 2. 
Identification of C T N N B 1  as a fusion partner of P L A G 1  in the t(3;8) 
translocation (Paper IV) 
Since Southern blot analysis of pleomorphic adenomas with 8ql2 
abnormalities had revealed rearrangements in the 5' non-coding region of 
PLAG1 we performed rapid amplification of 5' cDNA ends (5'-RACE) 
analysis on tumors with t(3;8) to identify a possible chimeric transcript 
consisting of sequences from 3p21 fused to PLAG1. Sequence analysis of the 
PCR products from two tumors revealed that ectopic sequences were fused 
to the acceptor splice site of exon 3 of PL AGI. BLAST analysis of these 
s e q u e n c e s  r e v e a l e d  t h a t  t h e y  w e r e  i d e n t i c a l  t o  e x o n  1  s e q u e n c e s  o f  C T N N B 1 ,  
a gene that has previously been mapped to chromosome 3p21 (Kraus et al., 
1994; Nollet et al., 1996). Independent evidence of the involvement of 
CTNNB1 in the 3;8-rearrangements was obtained by FISH using the two 
YACs 756G5 and 750D3, which contain the complete gene. Both YACs 
spanned the 3p21 breakpoint in an adenoma with an ins(8;3). 
Northern blot analysis revealed that C T N N B 1  is ubiquitously expressed, 
as a 3.8 kb RNA doublet in all tissues tested, normal salivary gland tissue 
included. The gene codes for ß-catenin, which is a cytoplasmic protein of 
about 88 kD (Gumbiner and McCrea, 1993). ß-catenin has been found as a 
structural component of adherence junctions, binding directly to Cadherins. 
The cadherin-ß-catenin complex mediates cell adhesion, cytoskeletal 
anchoring, and signalling, which are important processes in the regulation 
of cell growth and behaviour (Peifer, 1993; Kemier, 1993; Gumbiner, 1996). 
ß-catenin has also been implicated in the specification of cell fate during 
embryogenesis (Miller and Moon, 1996) as well as in the WG/WNT 
signalling pathway by virtue of its association with the adenomatous 
polyposis coli protein APC (Peifer, 1996). APC may act either as a negative 
regulator of ß-catenin accumulation and signalling or as a negative regulator 
and effector, with phosphorylation of APC by protein kinase GSK3ß as a 
controlling element (Rubinfeld et al., 1996). 
Recent studies have also shown that ß-catenin directly interacts with 
members of the TCF/LEF family of architectural transcription factors, such 
as LEF-1 (Behrens et al., 1996) or XTcf-3 (Molenaar et al., 1996), and that 
following nuclear translocation, it can regulate gene expression and activate 
specific target genes. Interestingly, LEF-1 has also been shown to regulate 
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epithelial-mesenchymal tissue interactions during organogenesis 
(Kratochwil et al., 1996). This is of particular interest since pleomorphic 
adenomas, which are epithelial tumors, clearly show both epithelial and 
mesenchymal differentiation. 
Detection of CTNNB1/PLAG1 fusion transcripts by RT-PCR (Paper IV) 
To extend and confirm the 5-RACE analysis, we applied a reverse 
transcription-polymerase chain reaction (RT-PCR) approach using primers 
specific for CTNNB1 and PLAG1. Analysis of 7 pleomorphic adenomas with 
t(3;8) (6 cases) or ins(8;3) (1 case) revealed hybrid transcripts consisting of 
CTNNB1 and PLAG1 sequences in all the tumors analyzed. Products of two 
different sizes were obtained, 509 bp and 614 bp. The larger product differs 
from the smaller by an extra 105 bp which corresponds to the alternatively 
spliced exon 2 of PL AGI. Both products were seen in five tumors, whereas 
in two cases only the smaller product could be detected. The identity of t hese 
PCR products  was  conf i rmed by  sequence  analys i s .  The  CTNNB1 /PLAG1 
fusion transcripts could not be detected in an adenoma with a variant 
translocation t(8;15)(ql2;ql4), demonstrating that these transcripts are 
spec i f ic  for  the  t (3 ;8) .  The  re c iproca l  fus io n  t ransc r ip t s  PLAG1 /CTNNB1 
encoded by the der(3), could also be readily detected by RT-PCR. Collectively, 
these data indicate that the breakpoints in all seven tumors with 3;8-
rearrangements had occurred in the 5' region of PL AGI, upstream of the 
non-coding exon 3. In CTNNB1 the breakpoints were always in the first 
intron. 
Activation of PL AGI expression due to promoter swapping (Paper IV) 
To evaluate the consequences of the 3;8-rearrangements on the 
expression of PL AGI and CTNNB1 we performed Northern blot analysis. 
All tumors tested expressed a 7.5 kb transcript using a probe specific for the 
3'UTR of PLAG1. This transcript was also detected with a probe specific for 
exon 1 of C TNNB1, demonstrating that it does not correspond to the normal 
PLAG1 transcript but to a CTNNB1/PLAG1 fusion transcript. This was also 
conf i rmed us ing  a  probe  spec i f i c  for  exon  1  of  PLAG1.  
In contrast to tumors with 3;8-rearrangements, the adenoma with the 
t(8;15)(ql2;ql4) only expressed the normal CTNNB1 transcripts in addition 
to the 7.5 kb transcript detected by the PLAG1 3'UTR probe. The expression 
levels of CTNNB1 was about twice as high as in tumors with a 
CTNNB1/PLAG1 fusion transcript. 5'-RACE analysis revealed that this 
tumor also has a breakpoint in the 5' region of PLAG1, and that the 
33 
translocation leads to a fusion transcript with ectopic sequences fused to 
exon 3 of PLAG1. The ectopic sequences consist of 38 nucleotides which do 
not correspond to any known gene sequences. 
Collectively, our findings demonstrate that the t(3;8) translocations lead 
to reciprocal exchange between expression control elements of PLAG1 and 
CTNNB1, leading to activation of PLAG1 and reduced expression of 
CTNNB1. Since the coding sequences of both genes are invariably preserved, 
we have described the molecular mechanism as promoter swapping. To the 
best of our knowledge this is the first example of promoter swapping in 
solid tumors. However, in leukemias and lymphomas there are a few 
known examples of promoter substitutions (Apian et al., -1992; Dallery et al ., 
1995; Galiègue-Zouitina et al., 1996). 
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SUMMARY 
The most frequent cytogenetic finding in pleomorphic adenomas is a 
t(3;8)(p21;ql2) translocation, or variants thereof in which the 8ql2->qter 
segment is translocated to a variety of other chromosome regions. Using a 
positional cloning approach we have identified the target genes affected by 
the t(3;8) in primary pleomorphic adenomas. Two non-overlapping YAC 
contigs, covering approximately 75% of band 8ql2, were established. FISH 
mapping of YACs and cosmids from these contigs revealed that the majority 
of b reakpoints clustered within a 300-kb subregion in the centromeric part of 
8ql2 .  Deta i led  mapping of  th is  region led  to  the  ident i f ica t ion of  the  PLAG1 
gene, a novel, developmentally regulated gene coding for a zinc finger 
protein. 5-RACE analysis of primary tumors with t(3;8) enabled us to 
ident i fy  CT NNB1 as  the  chromosome 3  gene fused to  PL AG1.  CTNNB1 
codes for ß-catenin, a protein interface functioning in the WG/WNT 
signalling pathway and specification of cell fate during embryogenesis. 
The t(3;8) results in promoter swapping between PLAG1 and CTNNB1.  
Fusions invariably occur in the 5' non-coding regions of both genes, 
exchanging regulatory control elements while preserving the coding 
sequences. Due to the t(3;8) PLAG1 is activated whereas the expression of 
CTNNB1 is reduced. Activation of PLAG1 was also observed in an adenoma 
with a t(8;15)(ql2;ql4) translocation, demonstrating that PLAG1 activation is 
not restricted to tumors with t(3;8). To our knowledge this is the first 
example of promoter swapping in solid tumors. 
The identification and cloning of a novel "benign oncogene" activated by 
chromosome translocation in pleomorphic adenomas constitute an 
important step towards an increased understanding of the molecular 
pathogenesis of benign neoplastic growth. The present findings may also 
have diagnostic implications. The fact that PLAG1 is not normally expressed 
in adult tissues, but activated in tumors as a result of 8 ql2 rearrangements, 
makes it a potentially useful marker in the differential diagnosis of benign 
and malignant salivary gland tumors. The results potentially allow for 
targeted therapy of pleomorphic adenomas. 
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